Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 12, 2019 (7 years ago)

Albuterol 3.75mg / Ipratropium 0.75mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Processing Controls

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Albuterol 3.75mg / Ipratropium 0.75mg, 3ML Vial, For Inhalation Only, Conversio Health, San Luis Obispo, CA 93401.

Drug: Albuterol

Recalling firm
Integrated Health Concepts Inc. dba Conversio Health
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0509-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Albuterol recalls

See all
Class III · Low risk

Albuterol Sulfate

Failed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.

Ongoing Stability / shelf life Cipla USA, Inc. NDC 69097-142-60 D-0593-2025
Class I · High risk

Albuterol Sulfate Inhalation Aerosol

Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

Terminated Packaging defect Cipla USA, Inc. NDC 69097-142-60 D-0938-2023

Other recalls by Integrated Health Concepts Inc. dba Conversio Health

All 2019 recalls